A Phase 2 interventional study of FTY720 and Placebo in Multiple Sclerosis, sponsored by Novartis. Completed at 26 sites in 11 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2017-09-15.
Sponsored by Novartis · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.
Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 12th largest by enrollment, is the only one that started in 2003, is one of 4 in phase 2, and was the 2nd registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States, Poland, Slovakia
Ages 10–17
Biogen
Ages 10–17
By country, each count listing its studies:
fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 13 · Phase 4 17
First in 2003; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 281 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 167 across the 34 interventional studies. Of the 28 that completed or were terminated, 23 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 6 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
106 studies in Multiple Sclerosis by Novartis: 9 open now, 24 under way, 6 of them phase 3. Of 78 finished, 45 (58%) have results posted.
Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 20th largest by enrollment of the 64 interventional ones that give a count, is the only one that started in 2003, is one of 12 in phase 2, and was the 2nd registered.
Novartis’s Multiple Sclerosis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing fingolimod in Multiple Sclerosis, from their registry updates:
Among Novartis’s 106 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
This study evaluated the safety, tolerability and effect on MRI lesion parameters of FTY720 in patients with relapsing multiple sclerosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Core Study
Inclusion Criteria:
Extension Study
Exclusion Criteria:
Core Study
Extension Study
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Core study: patients received fingolimod 1.25 mg, once daily for 6 months. Extension: In dose -blind period and open label, fingolimod 1.25 mg once daily for 9-18 months (6 months to 24 months). Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
Drug: FTY720
Core study: patients received placebo, once daily for 6 months. Extension: In dose-blind period patients were re-randomized into either fingolimod 1.25 mg or 5.0 mg once per day for 6-15 months. In open-label period patients received fingolimod 1.25 mg once per day for 15 to 24 months. Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
Drug: Placebo
Core study: patients received fingolimod 5.0 mg, once daily for 6 months. Extension: In dose-blind period fingolimod 5.0 mg once daily for 6-15 months. For open-label phase 15 to 24 months 1.25mg once daily. Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
Drug: FTY720
FTY720 capsule was taken orally once a day
Placebo 1.25 mg capsule was given once daily
Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 6 (Core)
Total number of post-baseline Gd-enhanced lesions is calculated as a sum of all Gd-enhanced lesions seen on post-baseline scans per visit. Real (not per slice) lesions are counted in this analysis.
Time frame: Month 6 (Core)
Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 12
Total number of post-baseline Gd-enhanced lesions is calculated as a sum of all Gd-enhanced lesions seen on post-baseline scans per visit. Real (not per slice) lesions are counted in this analysis.
Time frame: Month 12 (extension)
Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 60
Total number of post-baseline Gd-enhanced lesions is calculated as a sum of all Gd-enhanced lesions seen on post-baseline scans per visit. Real (not per slice) lesions are counted in this analysis.
Time frame: Month 60 (extension)
Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at End of Study
Total number of post-baseline Gd-enhanced lesions is calculated as a sum of all Gd-enhanced lesions seen on post-baseline scans per visit. Real (not per slice) lesions are counted in this analysis. The last observation was the last observation available for each patient which ranged from 1 to 2801 days
Time frame: Last observation (Up to 80 months in average)
Percentage of Participants Free of T1-weighted Lesions
A patient was defined as free of lesions if s/he had zero lesions. The last observation was the last observation available for each patient which ranged from 1 to 2801 days
Time frame: Baseline, Months 6 (core), 12, 60 and Last Observation (up to 80 months in average)
Percentage of Patients Free of Gd-enhanced T1-weighted and New T2- Weighted Lesions by Visit
A patient was defined as free of lesions if s/he had zero lesions. The sum of all new T2-weighted lesions at Month 1 to last observation was zero (the sum is missing if one of the assessments was missing). New T2 lesions at a specific visit were assessed relative to the previous visit scan. Exception: new T2 lesions at Month 24 were assessed relative to Month 12. The last observation was the last observation available for each patient which ranged from 1 to 2801 days
Time frame: Month 6 and 12, 60, last observation (up to 80 months in average)
Mean Number of New T2-weighted Lesions
New T2 lesions at a specific visit were assessed relative to the previous visit scan. The total number of lesions (Month 1 to end of study) is calculated as the sum of the number of lesions at Months 1 to 6, Month 12, Month 60 and last observation. The last observation was the last observation available for each patient which ranged from 1 to 2801 days
Time frame: (Core) Month 6 and (Extension) 12, 60, last observation (up to 80 months in average)
Volume of T2-weighted Lesions
Volume of total T2-weighted lesions by visit were summarized. The last observation was the last observation available for each patient which ranged from 1 to 2801 days
Time frame: (Core) Month 6 and (Extension) 12, 60, last observation (up to 80 months in average)
Change From Baseline in Volume of Total T2-weighted Lesions
Change in volume of total T2-weighted lesions by visit were summarized. Negative values indicate improvement (reduction in lesion volume) and positive values worsening (increase in lesion volume). The last observation was the last observation available for each patient which ranged from 1 to 2801 days.
Time frame: Baseline to month 6, 12, 60 and Last observation (up to 80 months in average)
Time to Event Analysis: Kaplan Meier Estimates of Percentage of Relapse-free Patients
The Expanded Disability Status Scale (EDSS) is a scale for assessing disability in 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel \& bladder, cerebral, other functions). An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the EDSS score based on the following criteria: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. Percent of patients free of disability progression was calculated using the Kaplan-Meier method. The last observation was the last observation available for each patient which ranged from 1 to 2801 days
Time frame: Month 6,12,60 and Last observation (up to 80 months in average)
Mean Trough Blood Concentrations of FTY720
For each patient, the arithmetic mean of the two FTY720 trough blood levels from month 3 and 6 was calculated. This was taken as the patient's steady-state trough levels. Venous blood samples (3 mL) were collected before the dose in ethylenediaminetetraacetic acid (EDTA)-containing tubes at protocol-scheduled visits at months 3 and 6 in all patients.
Time frame: Month 3 and 6
| Milestone | Placebo | Fingolimod (FTY720) 1.25 mg/Day | Fingolimod (FTY720) 5.0 mg/Day |
|---|---|---|---|
| Started | 93 | 94 | 94 |
| Completed | 86 | 88 | 82 |
| Not completed | 7 | 6 | 12 |
| Withdrew: Adverse event | 4 | 5 | 8 |
| Withdrew: Withdrawal by subject | 1 | 1 | 2 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 1 |
| Withdrew: Laboratory abnormality | 0 | 0 | 1 |
| Milestone | Placebo | Fingolimod (FTY720) 1.25 mg/Day | Fingolimod (FTY720) 5.0 mg/Day |
|---|---|---|---|
| Started | 83 | 87 | 80 |
| Completed | 40 | 45 | 37 |
| Not completed | 43 | 42 | 43 |
| Withdrew: Abnormal laboratory value | 3 | 2 | 2 |
| Withdrew: Administrative problems | 1 | 1 | 2 |
| Withdrew: Adverse event | 15 | 19 | 15 |
| Withdrew: Protocol violation | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 14 | 13 | 14 |
| Withdrew: Lack of efficacy | 7 | 4 | 7 |
| Withdrew: Patient no longer required study drug | 2 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 |
| Withdrew: Death | 0 | 1 | 0 |
Total number of post-baseline Gd-enhanced lesions is calculated as a sum of all Gd-enhanced lesions seen on post-baseline scans per visit. Real (not per slice) lesions are counted in this analysis.
| GD- enhanced T1 lesions | Placebo | Fingolimod (FTY720) 1.25 mg/Day | Fingolimod (FTY720) 5.0 mg/Day |
|---|---|---|---|
| Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 6 (Core) | 2.3 ± 4.23 | 1.4 ± 5.69 | 0.4 ± 0.82 |
A patient was defined as free of lesions if s/he had zero lesions. The last observation was the last observation available for each patient which ranged from 1 to 2801 days
| percentage of participants | Placebo | Fingolimod (FTY720) 1.25 mg/Day | Fingolimod (FTY720) 5.0 mg/Day |
|---|---|---|---|
| Baseline (Core) n=93, 92, 93 | 49.5 | 52.2 | 48.4 |
| Month 6 (Core) n= 83, 90, 87 | 47.0 | 76.7 | 78.2 |
| Month 12 (Extension) n= 72, 77, 71 | 79.2 | 83.1 | 88.7 |
| Month 60 (Extension) n= 45, 49, 44 | 91.1 | 91.8 | 93.2 |
| Last observation (Extension) n= 92, 93, 92 | 81.5 | 83.9 | 83.7 |
Total number of post-baseline Gd-enhanced lesions is calculated as a sum of all Gd-enhanced lesions seen on post-baseline scans per visit. Real (not per slice) lesions are counted in this analysis.
| GD- enhanced T1 lesions | Placebo | Fingolimod (FTY720) 1.25 mg/Day | Fingolimod (FTY720) 5.0 mg/Day |
|---|---|---|---|
| Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 12 | 0.4 ± 0.95 | 1.0 ± 5.81 | 0.2 ± 0.47 |
Total number of post-baseline Gd-enhanced lesions is calculated as a sum of all Gd-enhanced lesions seen on post-baseline scans per visit. Real (not per slice) lesions are counted in this analysis.
| GD- enhanced T1 lesions | Placebo | Fingolimod (FTY720) 1.25 mg/Day | Fingolimod (FTY720) 5.0 mg/Day |
|---|---|---|---|
| Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at Month 60 | 0.2 ± 0.7 | 0.2 ± 0.92 | 0.1 ± 0.55 |
Total number of post-baseline Gd-enhanced lesions is calculated as a sum of all Gd-enhanced lesions seen on post-baseline scans per visit. Real (not per slice) lesions are counted in this analysis. The last observation was the last observation available for each patient which ranged from 1 to 2801 days
| GD- enhanced T1 lesions | Placebo | Fingolimod (FTY720) 1.25 mg/Day | Fingolimod (FTY720) 5.0 mg/Day |
|---|---|---|---|
| Mean Number of Gadolinium (Gd)-Enhanced T1-weighted Lesions at End of Study | 0.8 ± 2.87 | 0.4 ± 1.39 | 0.5 ± 1.65 |
A patient was defined as free of lesions if s/he had zero lesions. The sum of all new T2-weighted lesions at Month 1 to last observation was zero (the sum is missing if one of the assessments was missing). New T2 lesions at a specific visit were assessed relative to the previous visit scan. Exception: new T2 lesions at Month 24 were assessed relative to Month 12. The last observation was the last observation available for each patient which ranged from 1 to 2801 days
| percentage of paticipants | Placebo | Fingolimod (FTY720) 1.25 mg/Day | Fingolimod (FTY720) 5.0 mg/Day |
|---|---|---|---|
| Month 6 (Core), n= 80, 87, 83 | 47.5 | 77.0 | 80.7 |
| Month 12 (Extension) n=70, 77, 70 | 57.1 | 67.5 | 72.9 |
| Month 60 (Extension) n=45, 49, 43 | 88.9 | 87.8 | 83.7 |
| Last observation (Extension) n=92, 93,90 | 72.8 | 76.3 | 78.9 |
New T2 lesions at a specific visit were assessed relative to the previous visit scan. The total number of lesions (Month 1 to end of study) is calculated as the sum of the number of lesions at Months 1 to 6, Month 12, Month 60 and last observation. The last observation was the last observation available for each patient which ranged from 1 to 2801 days
| GD enhanced T2 lesions | Placebo | Fingolimod (FTY720) 1.25 mg/Day | Fingolimod (FTY720) 5.0 mg/Day |
|---|---|---|---|
| Month 6 (Core), n= 82,88, 84 | 1.0 ± 2.37 | 0.5 ± 2.07 | 0.1 ± 0.34 |
| Month 12 (Extension) n=71, 79, 71 | 0.8 ± 1.41 | 1.4 ± 5.56 | 0.6 ± 1.10 |
| Month 60 (Extension) n=45, 50, 43 | 0.4 ± 1.25 | 0.5 ± 1.36 | 0.3 ± 0.97 |
| Last observation (Extension) n=92, 93, 91 | 0.7 ± 1.99 | 0.6 ± 1.51 | 0.5 ± 1.64 |
Volume of total T2-weighted lesions by visit were summarized. The last observation was the last observation available for each patient which ranged from 1 to 2801 days
| mm^3 | Placebo | Fingolimod (FTY720) 1.25 mg/Day | Fingolimod (FTY720) 5.0 mg/Day |
|---|---|---|---|
| Month 6 (Core) n=85, 91, 87 | 9016.0 ± 10361.83 | 10084.6 ± 14774.16 | 8331.1 ± 10162.01 |
| Month 12 (Extension) n= 73, 79, 72 | 8264.1 ± 10121.43 | 10707.1 ± 14887.66 | 8363.2 ± 10694.82 |
| Month 60 (Extension) n=45, 50, 44 | 6698.3 ± 9569.98 | 9498.7 ± 9765.60 | 6626.9 ± 9146.01 |
| Last observation (Extension) n=87, 91, 88 | 8757.2 ± 10127.01 | 10090.2 ± 13999.50 | 8061.8 ± 9003.47 |
Change in volume of total T2-weighted lesions by visit were summarized. Negative values indicate improvement (reduction in lesion volume) and positive values worsening (increase in lesion volume). The last observation was the last observation available for each patient which ranged from 1 to 2801 days.
| mm^3 | Placebo | Fingolimod (FTY720) 1.25 mg/Day | Fingolimod (FTY720) 5.0 mg/Day |
|---|---|---|---|
| Month 6 (core) n=85, 89, 86 | 146.15 ± 1683.602 | -115.81 ± 1031.799 | -607.97 ± 1705.486 |
| Month 12 (extension) n=73, 77, 71 | 144.96 ± 1513.577 | 1.66 ± 1714.731 | -513.35 ± 1943.338 |
| Month 60 (extension) n=45, 49, 43 | -621.82 ± 1338.966 | -204.09 ± 2238.182 | -1429.98 ± 3928.944 |
| Last observation (extension) n= 87, 89, 87 | -178.86 ± 1884.904 | -92.24 ± 3033.041 | -907.48 ± 2997.668 |
The Expanded Disability Status Scale (EDSS) is a scale for assessing disability in 8 functional systems (visual, brain stem, pyramidal, cerebellar, sensory, bowel \& bladder, cerebral, other functions). An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the EDSS score based on the following criteria: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. Percent of patients free of disability progression was calculated using the Kaplan-Meier method. The last observation was the last observation available for each patient which ranged from 1 to 2801 days
| percentage of participants | Placebo | Fingolimod (FTY720) 1.25 mg/Day | Fingolimod (FTY720) 5.0 mg/Day |
|---|---|---|---|
| 0 days (n=93,94,94) | 1.00 (1.000 to 1.000) | 1.00 (1.000 to 1.000) | 1.00 (1.000 to 1.000) |
| 200 days (n=57, 73, 70) | 0.69 (0.589 to 0.782) | 0.86 (0.786 to 0.929) | 0.86 (0.782 to 0.928) |
| 400 days (n=48, 63, 60) | 0.62 (0.520 to 0.725) | 0.78 (0.699 to 0.871) | 0.79 (0.707 to 0.878) |
| 600 days (n=41, 57, 52) | 0.58 (0.478 to 0.688) | 0.76 (0.669 to 0.849) | 0.78 (0.690 to 0.867) |
| 800 days (n=38, 48, 48) | 0.55 (0.477 to 0.662) | 0.75 (0.652 to 0.838) | 0.75 (0.653 to 0.843) |
| 1000 days (n=35, 42, 45) | 0.53 (0.416 to 0.634) | 0.70 (0.595 to 0.798) | 0.75 (0.653 to 0.843) |
| 1200 days (n=30, 38 40) | 0.51 (0.399 to 0.619) | 0.66 (0.55 to 0.770) | 0.70 (0.594 to 0.802) |
| 1400 days (n=29, 36, 35) | 0.51 (0.399 to 0.619) | 0.63 (0.516 to 0.739) | 0.70 (0.594 to 0.802) |
| 1600 days (n=27, 34, 34) | 0.51 (0.399 to 0.619) | 0.61 (0.496 to 0.724) | 0.68 (0.570 to 0.786) |
| 1800 days (n=25, 33, 33) | 0.51 (0.399 to 0.619) | 0.61 (0.496 to 0.724) | 0.68 (0.570 to 0.786) |
| 2000 days (n=23, 31, 31) | 0.51 (0.399 to 0.619) | 0.59 (0.475 to 0.707) | 0.66 (0.545 to 0.769) |
| 2200 days (n=22, 28, 30) | 0.49 (0.373 to 0.600) | 0.55 (0.433 to 0.673) | 0.66 (0.545 to 0.769) |
| 2400 days (n=21, 26, 27) | 0.46 (0.348 to 0.581) | 0.55 (0.433 to 0.673) | 0.66 (0.545 to 0.769) |
| 2600 days (n=9, 12, 12) | 0.44 (0.313 to 0.558) | 0.55 (0.433 to 0.673) | 0.66 (0.545 to 0.769) |
| 2880 days (n=0, 0, 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) |
For each patient, the arithmetic mean of the two FTY720 trough blood levels from month 3 and 6 was calculated. This was taken as the patient's steady-state trough levels. Venous blood samples (3 mL) were collected before the dose in ethylenediaminetetraacetic acid (EDTA)-containing tubes at protocol-scheduled visits at months 3 and 6 in all patients.
| ng/mL | FTY720 1.25 mg/Day | FTY720 5.0 mg/Day |
|---|---|---|
| Month 3 (core) | 7.64 ± 5.44 | 30.5 ± 18.8 |
| Month 6 (core) | 7.38 ± 4.57 | 28.9 ± 22.1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 25/93 (26.9%) | 86/93 (92.5%) |
| Fingolimod (FTY720) 1.25 mg | — | 19/94 (20.2%) | 88/94 (93.6%) |
| Fingolimod (FTY720) 5.0 mg | — | 32/94 (34%) | 92/94 (97.9%) |
| Event | Placebo | Fingolimod (FTY720) 1.25 mg | Fingolimod (FTY720) 5.0 mg |
|---|---|---|---|
| BradycardiaCardiac disorders | 1/93 | 0/94 | 3/94 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/93 | 1/94 | 3/94 |
| Macular oedemaEye disorders | 0/93 | 2/94 | 2/94 |
| Chest painGeneral disorders | 0/93 | 1/94 | 2/94 |
| CholelithiasisHepatobiliary disorders | 0/93 | 2/94 | 0/94 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/93 | 0/94 | 2/94 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/93 | 2/94 | 0/94 |
| AnxietyPsychiatric disorders | 0/93 | 2/94 | 0/94 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/93 | 0/94 | 2/94 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/93 | 0/94 | 0/94 |
| Event | Placebo | Fingolimod (FTY720) 1.25 mg | Fingolimod (FTY720) 5.0 mg |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 34/93 | 39/94 | 42/94 |
| HeadacheNervous system disorders | 28/93 | 35/94 | 25/94 |
| FatigueGeneral disorders | 22/93 | 23/94 | 16/94 |
| InfluenzaInfections and infestations | 16/93 | 23/94 | 22/94 |
| Back painMusculoskeletal and connective tissue disorders | 22/93 | 16/94 | 19/94 |
| Upper respiratory tract infectionInfections and infestations | 19/93 | 19/94 | 18/94 |
| CoughRespiratory, thoracic and mediastinal disorders | 12/93 | 16/94 | 19/94 |
| HypertensionVascular disorders | 13/93 | 19/94 | 10/94 |
| Alanine aminotransferase increasedInvestigations | 18/93 | 12/94 | 15/94 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 18/93 | 15/94 | 15/94 |
| Age, Continuous(Years) | Placebo | Fingolimod (FTY720) 1.25 mg/Day | Fingolimod (FTY720) 5.0 mg/Day | Total |
|---|---|---|---|---|
| Mean | 37.0 ± 8.80 | 38.1 ± 9.54 | 38.3 ± 10.51 | 37.8 ± 9.63 |
| Sex: Female, Male(Participants) | Placebo | Fingolimod (FTY720) 1.25 mg/Day | Fingolimod (FTY720) 5.0 mg/Day | Total |
|---|---|---|---|---|
| Female | 62 | 71 | 66 | 199 |
| Male | 31 | 23 | 28 | 82 |
The record gives a start of May 2003, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod